ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
4,987.14
-0.48%
US Tech 100
16,661.18
-1.62%
Dow Jones
37,985.01
0.55%
Brent Oil
87.08
0.77%
Bitcoin
64,148.00
1.00%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Delcath Systems Inc (DCTH) Quote

Delcath Systems Inc

Delcath Systems Inc (DCTH)

NASDAQ
4.65
-0.045
( -0.96% )
Updated: 12:49:00
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
4.65
Bid
4.65
Ask
4.66
Volume
143,776
4.62 Day's Range 4.77
2.25 52 Week Range 7.99
Market Cap
102.955M
Previous Close
4.695
Open
4.77
Last Trade
5
@
4.6501
Last Trade Time
12:49:56
Financial Volume
$ 676,262
VWAP
4.7036
Average Volume (3m)
207,504
Shares Outstanding
22,046,101
Dividend Yield
-
PE Ratio
-2.16
Earnings Per Share (EPS)
-2.16
Revenue
2.07M
Net Profit
-47.68M

About Delcath Systems Inc

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy... Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.delcath.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Delcath Systems Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DCTH. The last closing price for Delcath Systems was $4.70. Over the last year, Delcath Systems shares have traded in a share price range of $ 2.25 to $ 7.99.

Delcath Systems currently has 22,046,101 shares outstanding. The market capitalization of Delcath Systems is $102.96 million. Delcath Systems has a price to earnings ratio (PE ratio) of -2.16.

DCTH Latest News

More News

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEW YORK, April 4, 2024 NEW YORK, April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the...

April 04 2024
PR Newswire (US)

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update PR Newswire QUEENSBURY, N.Y., March 26, 2024 Increases 2024 Treatment Site Activation Guidance to 20...

March 26 2024
PR Newswire (US)

Delcath Systems Closes $7 Million Private Placement

Delcath Systems Closes $7 Million Private Placement PR Newswire NEW YORK, March 20, 2024 NEW YORK, March 20, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology...

March 20 2024
PR Newswire (US)

Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call

Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call PR Newswire NEW YORK, March 19, 2024 NEW YORK, March 19, 2024 /PRNewswire/ -- Delcath Systems...

March 19 2024
PR Newswire (US)

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer PR Newswire NEW YORK, March 18, 2024 NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the...

March 18 2024
PR Newswire (US)

Delcath Systems Announces $7 Million Private Placement

Delcath Systems Announces $7 Million Private Placement PR Newswire NEW YORK, March 15, 2024 NEW YORK, March 15, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional...

March 15 2024
PR Newswire (US)

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEW YORK, March 8, 2024 NEW YORK, March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH...

March 08 2024
PR Newswire (US)

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, March 8, 2024 NEW YORK, March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional...

March 08 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.34-6.813627254514.995.034.262230154.74970514CS
4-0.04-0.8528784648194.695.334.262737254.85003352CS
120.337.638888888894.325.333.72075044.5470319CS
260.8522.36842105263.85.332.252873593.71965986CS
52-0.98-17.4067495565.637.992.257306615.09838084CS
156-7.96-63.124504361612.6114.952.252732985.36568608CS
2600.8823.34217506633.7725.182.252370046.48109434CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.57k
TWGTop Wealth Group Holding Ltd
$ 2.95
(59.46%)
12.85M
NKGNNKGen Biotech Inc
$ 1.2957
(50.66%)
541.06k
CSLRComplete Solaria Inc
$ 0.3771
(42.30%)
5.93M
MNDRMobile health Network Solutions
$ 27.50
(35.00%)
5.36M
YYAIConnexa Sports Technologies Inc
$ 1.02
(-51.20%)
9.27M
SBFMSunshine Biopharma Inc
$ 2.0188
(-39.19%)
8.12M
IPDNProfessional Diversity Network Inc
$ 1.14
(-32.14%)
123.33k
BGLCBioNexus Gene Lab Corporation
$ 0.649899
(-23.42%)
550.48k
XPONExpion360 Inc
$ 2.4201
(-23.17%)
688.14k
EGOXNext e GO NV
$ 0.0486
(35.00%)
302.78M
SQQQProShares UltraPro Short QQQ
$ 12.7223
(5.40%)
122.23M
AGBAAGBA Group Holding Ltd
$ 1.32
(28.16%)
112.24M
SINTSiNtx Technologies Inc
$ 0.046
(15.00%)
87.3M
BSFCBlue Star Foods Corporation
$ 0.081
(25.78%)
71.8M

DCTH Discussion

View Posts
Monksdream Monksdream 4 weeks ago
DCTH 10Q due 3/26
👍️0
Filterthenoise Filterthenoise 3 months ago
$DCTH
👍️0
Filterthenoise Filterthenoise 5 months ago
Lets go $DCTH
👍️0
green maschine green maschine 8 months ago
6 now. That was quick.
👍️0
TheFinalCD TheFinalCD 8 months ago
5.80 HI :0)
👍️0
green maschine green maschine 8 months ago
The 5 analysts offering 12-month price forecasts for Delcath Systems Inc have a median target of 18.00, with a high estimate of 22.00 and a low estimate of 13.00. The median estimate represents a +216.62% increase from the last price of 5.69.
👍️0
dande1990 dande1990 8 months ago
H.C. Wainwright Reaffirms Their Buy Rating on Delcath Systems (DCTH)

TipRanks

 Aug. 15, 2023, 09:35 AM

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Delcath Systems (DCTH – Research Report), with a price target of $18.00. The company’s shares opened today at $5.84.
👍️0
dande1990 dande1990 8 months ago
HC Wainwright & Co. Maintains Delcath Systems (DCTH) Buy Recommendation

Story by George Maybach • 14h

?

Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 436.15% Upside
As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 436.15% from its latest reported closing price of 3.12.

👍️0
TheFinalCD TheFinalCD 8 months ago
5.13 LO :/


SO FAR
👍️0
green maschine green maschine 8 months ago
Hope you get that back working soon. I use TD Ameritrade and so far haven't had any problems with their system.
👍️0
dande1990 dande1990 8 months ago
No... On my app and my laptop I have a message saying they are unable to at the moment

$DCTH
👍️0
green maschine green maschine 8 months ago
Wow, bummer. Did they say why?
👍️0
dande1990 dande1990 8 months ago
Fidelity is down. Cant make trades at all.

$DCTH
👍️0
green maschine green maschine 8 months ago
Awesome! I need to get my correct my sleeping habits - kicking myself today.
👍️0
dande1990 dande1990 8 months ago
Ive been able to do 5.01 to 5.77 and 5.55 to 7.25. In again at 6.33.
👍️0
green maschine green maschine 8 months ago
Nice move CD. Still climbing. $$DCTH$$
👍️0
green maschine green maschine 8 months ago
I'm in at 5.43, went back to bed and missed the flip today. Oh well might see 10 by EOW.
👍️0
dande1990 dande1990 8 months ago
This board needs some life!! Lets go $DCTH
👍️0
TheFinalCD TheFinalCD 8 months ago
round ii

filled as low as 6.46 on that DIP

$DCTH
👍️0
TheFinalCD TheFinalCD 8 months ago
$7!!!!!!!!!!!!!!


SOLD SOME 6.95 AFTER 7 COULDNT BREAK HARD
👍️0
TheFinalCD TheFinalCD 8 months ago
6.70 LG!!!!!!
👍️0
SriMaharaj SriMaharaj 8 months ago
Told you guys. Get in now before it's too late.
👍️0
SriMaharaj SriMaharaj 8 months ago
Wait until it cross $6. You will see $10 today or tomorrow.
👍️0
TheFinalCD TheFinalCD 8 months ago
6.50 WAS A NICE POP OFF MY 5.55 ENTRY
👍️0
green maschine green maschine 8 months ago
Yeah there's resistance at that level, but I believe it'll break through today. Too much buying pressure here. FDA approval is huge news.
👍️0
Filterthenoise Filterthenoise 8 months ago
BOOM $DCTH
👍️0
TheFinalCD TheFinalCD 8 months ago
6.24 SO FAR BUT THEY QUICKLY SOLD IT OFF TO 5.34

DCTH
👍️0
Monksdream Monksdream 8 months ago
Early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
green maschine green maschine 8 months ago
Good morning. I wonder how high this flies today.
👍️0
TheFinalCD TheFinalCD 8 months ago
https://finviz.com/quote.ashx?t=DCTH&p=d

$DCTH 🚨 Approved

Finally after years of try.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma. pic.twitter.com/ZCBQZXbgzE— Ripster📈📉 (@ripster47) August 15, 2023
👍️0
green maschine green maschine 8 months ago
Where is everybody?
👍️0
Carlito78 Carlito78 8 months ago
What ever happened to SamnotSamuel?
👍️0
harvest1 harvest1 9 months ago
Wow stock is down 2 weeks before PDUFA date. Hard to imagine this wont be approved this time with no adcom. Not sure why there arent more buyers. Hopefully there is a pop on approval and they have a quick launch and revenue ramp.
👍️0
Filterthenoise Filterthenoise 1 year ago
Finally! Go $DCTH
👍️0
Jmma Jmma 1 year ago
Finally looks promising for real. Had shares few years ago and got chewed up and spit out . Reverse splits wiped out a lot of investors. Looks like they turned the corner and could become the investment everyone hoped for awhile back. Good luck to those holding.
👍️0
Filterthenoise Filterthenoise 1 year ago
No one loving the start of the run?
👍️0
Filterthenoise Filterthenoise 1 year ago
Next leg time LFG $DCTH!!
👍️0
Filterthenoise Filterthenoise 1 year ago
$DCTH... LFG!
👍️0
Filterthenoise Filterthenoise 1 year ago
Let's GO!

$DCTH
👍️0
Filterthenoise Filterthenoise 1 year ago
Another run at it coming

GLTA
👍️0
harvest1 harvest1 1 year ago
A new corporate presentation was posted to the company's website with alot of updated information.
https://delcath.com/investors/events-presentations/

This company has been left for dead by the market but I think the stock could recover strongly next year after approval if revenues begin to roll in. I would be interested to hear others thoughts on catalysts and stock price targets. I think at least a $100 million market cap should be expected on approval. Longer term at least $250 million market cap when revenues are material. Starting 3 new trials in 2023 will be positive as well. There appears to be little interest or attention for the company now but hopefully that changes after approval. My biggest fear is that they will have to dilute more at these awful rock bottom prices.
👍️0
Filterthenoise Filterthenoise 2 years ago
Here we go...
👍️0
nealhugh nealhugh 2 years ago
just waiting.........................................................................
👍️0
nealhugh nealhugh 2 years ago
yup--- good chat with GA... TY. Neal
👍️0
nealhugh nealhugh 2 years ago
FDA submission Summer/Fall 2022
FDA approval possible within 6 mos of submission

Fund raise? when?

Stock price lousy so wait for the fund raise?

All results on trials and use are good!

TY, Neal
👍️0
nealhugh nealhugh 2 years ago
https://ih.advfn.com/p.php?pid=nmona&article=87441339
👍️0
nealhugh nealhugh 2 years ago
Yeah--- I had Covid so I have been delayed!!! :)
👍️0
nealhugh nealhugh 2 years ago
Yeah--- I had Covid so I have been delayed!!! :)
👍️0
highstreettrader highstreettrader 2 years ago
Better call Toronto!! Lol
👍️0
nealhugh nealhugh 2 years ago
6.12-------------crazy!!! porque???
👍️0

Your Recent History

NASDAQ
DCTH
Delcath Systems
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved